Doravirine (Pifeltro®) is indicated in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||06/12/2018|
|Rapid review completed||16/01/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that doravirine (Pifeltro®) not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.